Phase II Trial of Natalizumab (Tysabri) Plus Prednisone for Initial Therapy of Acute Graft Versus Host Disease (aGVHD) of the Gastrointestinal Tract
Phase of Trial: Phase II
Latest Information Update: 07 Apr 2017
At a glance
- Drugs Natalizumab (Primary) ; Methylprednisolone
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 26 Jan 2016 According to ClinicalTrials.gov record, the treatment table has been updated.
- 29 Jan 2015 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.
- 27 Jan 2015 Planned End Date changed from 1 Jul 2022 to 1 Mar 2020, reported by ClinicalTrials.gov.